New Delhi: Famous pharmaceutical company Zydus Cadila on Thursday sought approval from the Emergency Use Authority (EUA) for the launch of its ZyCoV-D vaccine. Sources said the company has applied to the Drugs Controller General of India (DCGI), seeking emergency use approval for children aged 12 years and above. The company has claimed that the vaccine has completed Phase III testing.
ZyCoV-D is a DNA covid vaccine, which carries the genetic code of the part of the virus that triggers the body’s immune system. This will be the second indigenous COVID-19 vaccine to apply for such authorization as well as the world’s first DNA vaccine against coronavirus.
Zydus has claimed that its vaccine is 66.6 percent effective on symptomatic covid and it is 100 percent effective on disease beyond that. It has also been said by the company that this vaccine is safe for children between 12 and 18 years. However, trial date has not yet been peer reviewed.
It has been said from the company that the trial of ZyCoV-D vaccine has been done on 28000 volunteers across the country and the results of all have been safe and effective. The company said that 1000 of these volunteers were between the ages of 12 and 18. It has been said from the company side that this three-dose vaccine will be ‘needle free’ i.e. needleless.
